GFAP and Alzheimer disease: Similarly, GCD&GAN features demonstrated an AUC of 0.862 for distinguishing MCI+ from MCI-, with GFAP (AUC = 0.933) and p-tau217 (AUC = 0.986) enhancing predictive performance.<h4>Conclusion</h4>This study provides evidence that dual-task gait assessments, when combined with plasma biomarkers such as GFAP and p-tau217, may improve the discriminatory power for identifying AD-related MCI.